Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 8/20 | 0.77 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | G6PD | P11413 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29492572 | 1.00 | SERPINE1 (0.77) | SERPINE1CNR1POLBG6PDGRIK1 | |
| SCHEMBL22468222 | 0.99 | SERPINE1 (0.75) | SERPINE1CNR1POLBG6PDGRIK1 | |
| Tromethamine SCHEMBL1019735 | 0.93 | SERPINE1 (0.68) | SERPINE1CNR1POLBG6PDGRIK1 | |
| SCHEMBL1012706 | 0.92 | SERPINE1 (0.80) | SERPINE1CNR1POLBG6PDGRIK1 | |
| SCHEMBL1015662 | 0.90 | SERPINE1 (0.64) | SERPINE1CNR1POLBMAPTKDM4E | |
| SCHEMBL29448187 | 0.90 | SERPINE1 (0.64) | SERPINE1CNR1POLBG6PDMAPT | |
| SCHEMBL1014817 | 0.89 | SERPINE1 (0.76) | SERPINE1CNR1POLBG6PDGRIK1 | |
| SCHEMBL1015034 | 0.89 | SERPINE1 (0.69) | SERPINE1CNR1POLBG6PDGRIK1 | |
| SCHEMBL20814655 | 0.88 | SERPINE1 (0.61) | SERPINE1CNR1POLBG6PDGRIK1 | |
| SCHEMBL29492570 | 0.88 | SERPINE1 (0.59) | SERPINE1CNR1POLBMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713445-A2 | RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (TPA) FRAGMENTS AND USES THEREOF | Versiti Blood Research Institute Foundation, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| WO-2024238942-A2 | RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (TPA) FRAGMENTS AND USES THEREOF | VERSITI BLOOD RESEARCH INSTITUTE FOUNDATION, INC. (US) | 2024-11-21 | — | — | WO | claimed |
| US-20240216372-A1 | THERAPEUTICS FOR KELOIDS AND OTHER FIBROTIC DISORDERS | NATIONAL INSTITUTES OF HEALTH | 2024-07-04 | — | — | US | claimed |
| US-20220170940-A1 | BIOMARKER WITH THERAPEUTIC IMPLICATIONS FOR PERITONEAL CARCINOMATOSIS | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2022-06-02 | — | — | US | claimed |
| US-20220079911-A1 | USES OF PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) INHIBITORS | EIRION THERAPEUTICS, INC. | 2022-03-17 | — | — | US | claimed |
| EP-3948291-A1 | BIOMARKER WITH THERAPEUTIC IMPLICATIONS FOR PERITONEAL CARCINOMATOSIS | Singapore Health Services Pte. Ltd. (SG) | 2022-02-09 | — | — | EP | claimed |
| EP-3849539-A1 | PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) INHIBITORS AND USES THEREFOR | Eirion Therapeutics, Inc. (US) | 2021-07-21 | — | — | EP | claimed |
| EP-3849540-A1 | USES OF PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) INHIBITORS | Eirion Therapeutics, Inc. (US) | 2021-07-21 | — | — | EP | claimed |
| CN-113056269-A | Use of plasminogen activator inhibitor 1(PAI-1) inhibitors | 艾里奥治疗公司 | 2021-06-29 | — | — | CN | claimed |
| CN-113056268-A | Plasminogen activator inhibitor 1(PAI-1) inhibitors and uses thereof | 艾里奥治疗公司 | 2021-06-29 | — | — | CN | claimed |
| WO-2020056160-A1 | PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) INHIBITORS AND USES THEREFOR | EIRION THERAPEUTICS, INC. (US) | 2020-03-19 | — | — | WO | claimed |
| WO-2020056191-A1 | USES OF PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) INHIBITORS | EIRION THERAPEUTICS, INC. (US) | 2020-03-19 | — | — | WO | claimed |
| US-8415479-B2 | Inhibitor of plasminogen activator inhibitor-1 | RENASCIENCE CO., LTD. (JP) | 2013-04-09 | — | — | US | claimed |
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | RENASCIENCE CO., LTD. (JP) | 2011-05-12 | — | — | US | claimed |
| EP-2272822-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | Renascience CO., LTD. (JP) | 2011-01-12 | — | — | EP | claimed |
| EP-4713445-A2 | RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (TPA) FRAGMENTS AND USES THEREOF | Versiti Blood Research Institute Foundation, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12383579-B2 | Materials and methods of using an inhibitor of plasminogen activation to treat anastomotic leak | THE UNIVERSITY OF CHICAGO (US) | 2025-08-12 | — | — | US | disclosed |
| US-8415479-B2 | Inhibitor of plasminogen activator inhibitor-1 | RENASCIENCE CO., LTD. (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | RENASCIENCE CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| EP-2272822-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | Renascience CO., LTD. (JP) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383579-B2 | Materials and methods of using an inhibitor of plasminogen activation to treat anastomotic leak | PLAT, PLG, SERPINB10 | SERPINE1 4/4885CNR1 4379/4885POLB 809/4885 |
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | SERPINE1, SERPINB1, SERPINC1 | SERPINE1 1/4885CNR1 3950/4885POLB 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.